For the year ending 2025-12-31, ALKS had $828,630K increase in cash & cash equivalents over the period. $480,334K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Total revenues | 1,475,899 |
| Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) | 196,457 |
| Alixorexton | 95,763 |
| Lybalvi | 18,757 |
| Other external r&d expenses | 52,759 |
| Total external r&d expenses | 167,279 |
| Employee-related | 125,955 |
| Occupancy | 13,001 |
| Depreciation | 5,605 |
| Other internal r&d expenses | 12,124 |
| Total internal r&d expenses | 156,685 |
| R&d expenses | 323,964 |
| Selling and marketing expense | 480,011 |
| General and administrative expense | 221,511 |
| Total selling, general and administrative expense | 701,522 |
| Other segment (expense) income | 12,292 |
| Net income from continuing operations | 241,664 |
| Net income | 241,664 |
| Depreciation and amortization | 27,165 |
| Share-based compensation expense | 98,716 |
| Deferred income taxes | 28,774 |
| Other non-cash charges | 5,311 |
| Receivables | -50,503 |
| Contract assets | -4,990 |
| Inventory | 14,061 |
| Prepaid expenses and other assets | -852 |
| Right-of-use assets | -7,549 |
| Accounts payable and accrued expenses | 100,893 |
| Accrued sales discounts, allowances and reserves | -25,326 |
| Contract liabilities | -1,249 |
| Operating lease liabilities | -10,320 |
| Other long-term liabilities | 5,293 |
| Cash flows provided by operating activities | 520,754 |
| Additions of property, plant and equipment | 40,420 |
| Proceeds from the sale of property, plant and equipment | 1,086 |
| Proceeds from the sale of the athlone facility | 1,708 |
| Purchases of investments | 364,369 |
| Sales and maturities of investments | 697,492 |
| Cash flows provided by (used in) investing activities | 295,497 |
| Proceeds from the issuance of ordinary shares under share-based compensation arrangements | 43,411 |
| Employee taxes paid related to net share settlement of equity awards | 31,032 |
| Cash flows provided by (used in) financing activities | 12,379 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 828,630 |
| Cash, cash equivalents and restricted cash - beginning of period | 291,146 |
| Cash, cash equivalents and restricted cash - end of period | 1,119,776 |
Alkermes plc. (ALKS)
Alkermes plc. (ALKS)